Subscribe To
SNN / What Makes Smith & Nephew (SNN) a New Buy Stock
SNN News
By Proactive Investors
November 3, 2023
Smith & Nephew downgrade cycle coming to an end
JPMorgan has upgraded the firm to overweight from neutral pointing out shares have de-rated to 10-year lows in recent weeks. This reflected concerns o more_horizontal
By Proactive Investors
November 2, 2023
Smith & Nephew shares up 4.2% on FY sales upgrade
Shares in Smith & Nephew PLC (LSE:SN) surged by 4.2% as the company projected sales growth to hit the upper end of its guidance following a robust thi more_horizontal
By Zacks Investment Research
September 29, 2023
Should Value Investors Buy Smith & Nephew SNATS (SNN) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Neverthe more_horizontal
By Zacks Investment Research
September 4, 2023
Smith & Nephew (SNN) Loses -5.98% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Smith & Nephew (SNN) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with s more_horizontal
By Seeking Alpha
August 4, 2023
Smith & Nephew plc (SNN) Q2 2023 Earnings Call Transcript
Smith & Nephew plc (NYSE:SNN ) Q2 2023 Earnings Conference Call August 3, 2023 3:30 AM ET Company Participants Deepak Nath - Chief Executive Officer A more_horizontal
By Proactive Investors
August 3, 2023
Smith & Nephew raises guidance after strong first half
Smith & Nephew PLC (LSE:SN) reported improved revenue, profit and margin in the first half making progress towards achieving sustainable higher growth more_horizontal
By Seeking Alpha
August 1, 2023
Smith & Nephew: Entering New Markets But Growth Is Slow Still
Smith & Nephew plc is a long-standing company in the medical device sector, focusing on developing and manufacturing internationally. The company has more_horizontal
By Proactive Investors
April 26, 2023
Smith & Nephew holds guidance as revenue rises 3.8%
Smith & Nephew PLC (LSE:SN) held full-year guidance as it reported strong growth in its Sports Medicine and Advanced Wound Management businesses had u more_horizontal